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Abstract: Discovery and development of new antitumor agents from abundant marine fish 
are attracting an increasing interest. In the present study, we extracted and purified a novel 
antitumor protein Syngnathusin from the whole body of Syngnathus acus L., a precious 
marine fish traditionally used for tumors. Syngnathusin was comprised of 16 kinds of amino 
acids, mainly acidic amino acids. Its molecular weight was 67.3 kDa and its isoelectric point 
was 4.57. The N-terminal amino acid sequence of Syngnathusin was determined to be 
Lys-Arg-Asp-Leu-Gly-Phe-Val-Asp-Glu-Ile-Ser-Ala-His-Tyr  and showed no significant 
homology with the known proteins. Syngnathusin could significantly inhibit the growth of 
A549 and CCRF-CEM cells. However, the obvious proliferation inhibition against human 
non-tumor cell lines was not observed. Flow cytometry, morphologic assessment and comet 
assay revealed that Syngnathusin could induce apoptosis in A549 and CCRF-CEM cells and 
strongly cooperated with MTX. Syngnathusin could inhibit the growth of S180 tumor 
transplanted in mice. Syngnathusin may be developed as a novel, selective and effective 
antineoplastic agent. 
Keywords: Syngnathus acus; purification; characterization; antitumor; protein 
Abbreviations: CTX, cytoxan; 5-Fu, 5-fluorouracil; HCF, human uterine cervical canal 
fibroblast; HE-21, human embryonic fibroblast; HFL-1, human embryonic lung fibroblast; 
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HL-7702, human normal liver cells; IEF-PAGE, isoelectric focusing-polyacrylamide gel 
electrophoresis; MALDI-TOF-MS, matrix-assisted laser desorption/ ionization time of 
flight mass spectrometry; MTT, methyl thiazolyl tetrozolium; MTX, methotrexate; PBMC, 
human normal peripheral blood mononuclear cells; PI, propidium iodide; PVDF, 
polyvinylidene difluoride; Rp-HPLC, reversed-phase high performance liquid chromatography; 
RPTEC, human normal renal proximal tubule epithelial cells; SDS-PAGE, sodium 
dodecylsulphate-polyacrylamide gel electrophoresis; SI, Synergism index; Tris, trisamine. 
 
1. Introduction 
The modern research on traditional Chinese drugs has for a long time largely focused on the 
micromolecular constituents. However, recently, more and more researches have revealed some proteins 
and polypeptides e.g., lumbrukinase, hirudin and trichosanthin, possess the potent activities also. Some 
proteins and polypeptides from traditional Chinese drugs, especially from animal origin medical 
material, such as anthoplerintoxin, katsutoxin, snake venom, melittin, dolastatins and didemnins, exhibit 
significant antitumor activities [1,2]. Some experimental antitumor proteins derived from animal origin 
medical material have entered the clinical trials [3]. Marine fish, about 13,000 species, are a large and 
diverse group of animals containing high levels of protein, and more than 100 species are traditional 
medicines for tumors. However, only a tiny part of marine fish species were analyzed chemically and 
explored. Furthermore, most of the natural products derived from marine fish were evaluated and 
developed as functional food and these kinds of products were dominated by low molecular-weight 
compounds. Recently, a few proteins from marine fish such as shark, globefish, devil ray (Manta 
birostris), king crab, and hairy clam (Arca subcrenata) were reported to possess the potent antitumor 
activity [4–6]. Protamine and fish anti-bacterial peptides were also found to inhibit tumors [7,8]. Marine 
fish proteins represent an essentially unexploited resource for the discovery and development of 
potential antitumor drugs.  
In screening for antitumor protein from marine fish, pipefish have drawn much attention for their life 
characteristic and medical property. Pipefish, like their seahorse relatives, are remarkable for their 
adaptations for parental care, with females depositing eggs in male’s specialized incubating area where 
embryos are protected, nourished and osmoregulated. As an important medical pipefish with a medicinal 
history of more than 500 years, Syngnathus acus L. has been recorded in the Chinese Pharmacopoeia for 
cancer and impotency [9]. S. acus, widely distributed in the Pacific, Indian, Atlantic Ocean and 
Mediterranean Sea, contains a high level of protein, fatty acids and a small quantity of steroids [10,11]. 
The modern research found that the lipid-soluble constituents had the antitumor activity in vitro [12], 
harmonic effect [13,14] and anti-fatigue effect [15,16]. In traditional Chinese medicine, medical pipefish 
was used as aqueous extract for various cancers and other diseases. Some research also revealed that the 
water extract possessed the antitumor activity [17–19]. So, the water-soluble constituents in S. acus, 
especially proteins, deserve thorough investigation. However, the relevant research has not been 
reported yet. In the present study, antitumor protein in S. acus was investigated for the first time. As Mar. Drugs 2012, 10 37 
 
 
result, a novel protein Syngnathusin was purified and found to possess the potent antitumor in vivo and 
in vitro.  
2. Results and Discussion 
2.1. Bioassay-Guided Isolation in Vitro 
Crude protein of Syngnathus acus (CPSA) was isolated by ammonium sulfate saturation and then 
subjected to the antiproliferative assay against tumor cells. The results showed that CPAS suppressed the 
proliferation of A549, and CCRF-CEM cells, with the IC50 values less than 500 μg/mL (Table 1). 
Table 1. The antiproliferative activities of protein samples against four tumor cell lines  
(IC50, μg/mL ± SD, n = 3). 
Sample Yield  (mg) 
a  Tumor Cell Lines 
A549 L1210  CCRF-CEM  LoVo 
CPAS  1289  232.5 ± 47.1  2369.8 ± 104.7  438.6 ± 130.7  3125.1 ± 432.0
P1  189  1433.6 ± 216.2  3077.1 ± 280.5  1257.7 ± 141.8  4561.4 ± 216.5
P2  266  897.4 ± 155.7  1564.3 ± 233.9  1021.6 ± 213.3  935.0 ± 122.7
P3  83  1561.0 ± 185.4  906.6 ± 214.0  1309.5 ± 176.4  3201.3 ± 240.1
P4  168  84.9 ± 17.7  1446.1 ± 153.7  215.3 ± 38.1  1706.4 ± 186.7
P5  56  1035.6 ± 147.9  2876.6 ± 178.4  710.5 ± 164.2  2543.3 ± 307.4
S1  110  371.4 ± 83.5  1489.7 ± 211.9  688.1 ± 235.5  2359.9 ± 187.2
S2  27  27.6 ± 5.3  416.3 ± 91.5  44.9 ± 6.2  814.7 ± 143.6
a The weight of protein extracted from 100 g medical material. 
In order to screen the antitumor components, CPAS was purified by ion-exchange chromatography. 
Five A280 nm peak fractions, P1, P2, P3, P4 and P5, were obtained through elution with increasing NaCl 
concentrations on DEAE Sepharose column (Figure 1). In the antiproliferative evaluation of five 
fractions above, the fraction P4 exhibited the significant inhibition on the proliferation of A549 and 
CCRF-CEM cells with the IC50 values of 84.9 and 215.3 μg/mL, respectively (Table 1). The other 
fractions did not obviously inhibit the tumor cells’ proliferation. The results suggested that the fraction 
P4 deserved the further purification in order to elucidate the active constituents in S. acus. 
Fraction P4 was subjected to gel filtration chromatography for the further purification. Two A280 nm 
peak fractions, S1 and S2, were obtained (Figure 2). The results of the antitumor activity evaluation  
in vitro suggested the fraction S2 had the potent activity to suppress the proliferation of tumor cells of 
A549 and CCRF-CEM, with the values of IC50 less than 50 μg/mL; while the fraction S1 only showed 
the weak inhibition proliferation activity (Table 1).  
In order to determine whether protein S1 and S2 exhibit the proliferation inhibition against human 
non-tumor cells, six non-tumor cell lines were treated by protein samples. The IC50 values were more 
than 10 mg/mL, indicating protein S1 and S2 had no obvious inhibition proliferation activity to human 
non-tumor cells (Table 2). For the higher antitumor activities in vitro, the further investigation of protein 
S2 is warranted.  Mar. Drugs 2012, 10 38 
 
 
Figure 1. Purification of the crude protein of S. acus by ion-exchange chromatography on a 
DEAE-Sepharose Fast Flow column. Column dimensions: 2.5 cm × 50 cm. Flow rate:  
1.0 mL/min. The elution profile was monitored by spectrophotometry at 280 nm. Peak P1, 
P2, P3, P4 and P5 were eluted by 0, 0.1, 0.2, 0.3 and 0.5 M NaCl prepared in 20 mM 
Tris-HCl buffer (pH 8.0), respectively. 
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Figure 2. Purification of the DEAE chromatographic fraction P4 by gel filtration 
chromatography on a Superdex 75 column. Column dimensions: 2.0 cm × 30 cm. The 
elution was performed with 20 mM Tris-HCl containing 0.2 M NaCl at a flow of 1.0 mL/min. 
The elution profile was monitored by reading the absorbance at 280 nm. 
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Table 2. The antiproliferative activities of protein samples against six human non-tumor cell 
lines (IC50, mg/mL ± SD, n = 3). 
Sample 
Non-Tumor Cell Lines 
HCF HE-21  HFL-1  HL-7702  PMBC  RPTEC 
S1  30.1 ± 4.5  14.5 ± 3.1  25.3 ± 3.6  23.1 ± 4.3  28.9 ± 5.2  37.4 ± 6.2 
S2  21.4 ± 2.3  33.9 ± 2.8  17.9 ± 1.8  26.3 ± 3.0  40.6 ± 5.3  32.5 ± 5.8 Mar. Drugs 2012, 10 39 
 
 
2.2. Characterization of Purified Protein 
The molecular weight of protein S2 was estimated by SDS-PAGE, with molecular weight marker 
ranging from 14.4 to 116.0 kDa as standard. According to the calibration curve, the molecular weight of 
S2 was 67 kDa (Figure 3). The accurate molecular weight was 67.3 kDa determined by 
MALDI-TOF-MS (Figure 4). The IEF-PAGE result showed that the isoelectric point of protein S2 was 
4.57 (Figure 5). Protein S2 exhibited a single band in both SDS-PAGE and IEF-PAGE, and showed a 
single peak in Rp-HPLC (Figure 6). The results indicated protein S2 was a homogeneous protein. 
Figure 3. Purity and molecular mass analysis of protein S2 by SDS-PAGE using 5% 
stacking and 12% resolving polyacrylamide gel. 
 
Figure 4. The MALDI-TOF-MS analysis of protein S2 (positive ion mode).  
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Figure 5. Isoelectric point determination of protein S2 by using immobilized pH gradient 
isoelectric focusing-polyacrylamide gel electrophoresis. 
 
Figure 6. Rp-HPLC profile of S2. Performed on an Agilent 1200 HPLC system fitted with a 
C4 Hypersil column (5 μm, 300 Å, 4.6 mm × 250 mm). The elution solvent system was 
water-trifluoroacetic acid (solvent A; 100:0.005, v/v) and acetonitrile-trifluoroacetic acid 
(solvent B; 100:0.005, v/v). Isocratic elution 97% of solvent A for 15 min at flow rate of  
1.0 mL/min. Detection wavelength was set at 280 nm and column temperature was 25 °C. 
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No glucose was detected in protein S2 by the carbohydrate content assay, indicating it was a 
nonglycoprotein. The amino acid analysis showed that protein S2 contained 16 kinds of amino acid, 
mostly acidic amino acid. Protein S2 was particularly rich in aspartic acid, glutamic acid, histidine and 
phenylalanine (Table 3).  
Table 3. The amino acid composition of protein S2. 
Amino Acid  Weight (%)  Mol (%) 
Ala 5.08  7.51 
Arg 5.89  4.45 
Asp 14.76 14.60 
Cys 0.30  0.33 
Glu 12.57 11.32 
Gly 4.80  8.43 
His 10.19 8.65 
Ile 4.27 4.29 
Leu 6.73  6.76 
Lys 6.49  5.85 
Met 0.79  0.70 
Phe 10.59  8.44 
Ser 4.54 5.68 
Thr 3.23  3.57 
Tyr 3.87 2.81 
Val 5.89 6.62 
Total 99.99 100.01 
The N-terminal 14 amino acids sequence of S2 was determined to be Lys-Arg-Asp-Leu-Gly-Phe- 
Val-Asp-Glu-Ile-Ser-Ala-His-Tyr, indicating that its N-terminus was unblocked. This sequence was 
blasted in NCBI database. The results showed that it was a novel protein, since a data bank search could 
not detect any homologue with the available sequence. Protein S2 was named Syngnathusin, according 
to its origin. 
2.3. Antitumor Activities 
2.3.1. Antitumor Activities in Vivo 
Protein Syngnathusin inhibited the growth of implanted S180 solid tumors in mice at doses from  
10 mg/kg to 90 mg/kg in a dose-dependent manner. Its antitumor activity in vivo was very obvious 
(inhibition ration surpassed 30%), indicating that the efficiency of Syngnathusin was more apparent  
in vivo studies than in vitro (Figure 7). However, the apparent antitumor activity of Syngnathusin was 
not observed in H22 mice cancer model (data not given), indicating the antineoplastic activtity of 
Syngnathusin was selective.  Mar. Drugs 2012, 10 42 
 
 
Figure 7. Effect of protein Syngnathusin on the tumor weight (n = 10). Compared with NS,  
* p ≤ 0.05, ** p ≤ 0.01. 
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2.3.2. Induction of Apoptosis in Tumor Cells 
2.3.2.1. Effect on Tumor Cells Cycle  
To further evaluate the antitumor activity of Syngnathusin, the effect on the cell cycle phase 
distribution of A549 cells in the cell cycle was examined by flow cytometry analysis. The percentage of 
apoptotic cells was performed by PI staining. Compared with the control group (0.7%), the proportion of 
apoptotic cells in sample treated group increased progressively in A549 cells. When the concentration 
arrived at 200 and 1000 mg/mL, the proportion of apoptotic cells was 20.4 and 43.4%, respectively 
(Figure 8). The result showed that Syngnathusin could induce the apoptosis in a dose-dependent manner. 
Figure 8. Effect of protein Syngnathusin on A549 cell cycles. (A) blank; (B) 0.04 mg/mL for 
24 h; (C) 0.2 mg/mL for 24 h; (D) 1.0 mg/m for 24 h.  
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2.3.2.2. Comet Assay 
To further understand the molecular events underlining the Syngnathusin on tumor cells, DNA ladder 
assay was performed to study the apoptosis induced by Syngnathusin. Although the fragmentation was 
not observed in the cells treated with 0.25 mg/mL, the agarose electrophoresis of DNA from the cells 
treated with 0.5 and 1.0 mg/mL Syngnathusin did display DNA ladders, demonstrating that the obvious 
apoptosis occurred (Figure 9).  
Figure 9. DNA degradation in A549 cells treated with Syngnathusin. The total DNA was 
extracted and analyzed by electrophoresis on 1.0% agarose gel. 1: control; 2: treated with 
Syngnathusin (0.25 mg/mL) for 24 h; 3: treated with Syngnathusin (0.5 mg/mL) for 24 h;  
4: treated with Syngnathusin (1.0 mg/mL) for 24 h; M: 100 bp DNA Marker. 
 
2.3.2.3. Effect on Tumor Cells Morphology 
Under the fluorescent microscope, the morphology changes of A549 cells were observed. The 
untreated cells were stained evenly blue fluorescence which showed the chromatin equably distributed 
in nucleolus and displayed normal, healthy shape demonstrated by the clear skeletons (Figure 10A). 
However, the morphology of the cells started to change after treatment with Syngnathusin. The cells 
incubation with the different concentrations of Syngnathusin for 24 h displayed chromatin congregated 
and nucleolus pyknosis, which emitting bright fluorescence, the early phenomena of apoptosis; the cells 
detached from the substratum, became round in shape. Membrane bulge and detachment from 
cytoplasmic inclusion were also observed in the cells treated with Syngnathusin (Figure 10B–D).  Mar. Drugs 2012, 10 44 
 
 
Figure 10. Effect of protein Syngnathusin on A549 cells morphology, detected by 
fluorescence microscope with Hoechst 33342 staining. (A) blank; (B) 0.04 mg/mL;   
(C) 0.2 mg/mL; (D) 1.0 mg/mL. 
 
2.3.3. Cooperation with Chemotherapeutics 
To further evaluate the antitumor activity of Syngnathusin, its synergetic effects with commonly used 
chemotherapeutics were studied. Although Syngnathusin was not observed to strengthen the 
proliferation inhibition of MTX toward LH1210 cells, the results did show that Syngnathusin could 
enhance the antitumor activity of MTX toward CCRF-CEM cells. The synergism index (SI) was 2.0, 
indicating there was an obvious synergetic effect between MTX and Syngnathusin (Table 4). 
Table 4. The synergistic inhibition of combination with protein Syngnathusin and commonly 
use chemotherapeutics (n = 3). 
Synergism drug 
SI 
CCRF-CEM L1210 
MTX  2.0 ± 0.2  0.9 ± 0.1 
5-Fu  0.8 ± 0.1  0.8 ± 0.1 
Syngnathusin concentration: 0.20 mg/mL; MTX concentration: 0.13, 0.25, 0.50 μg/mL; 5-Fu 
concentration: 2.5, 5.0, 10 μg/mL. SI ≥ 1.5, synergetic effect; SI ≤ 0.5, antagonistic effect; 0.5 < RI < 1.5, 
additive effect. 
The synergetic effect with Syngnathusin and MTX was further evaluated by flow cytometer with 
Annexin V-PI double staining. The results suggested that both early apoptotic cells and non-viable 
apoptotic cells were increased in wider band, indicating Syngnathusin enhanced the CCRF-CEM cells 
apoptosis induced by MTX (Figure 11). Mar. Drugs 2012, 10 45 
 
 
Figure 11. Combination effect of protein Syngnathusin and MTX on CCRF-CEM cells. 
Treated for 24 h. (A) control; (B) 0.20 mg/mL Syngnathusin; (C) 0.25 μg/mL MTX;   
(D) 0.20 mg/mL Syngnathusin + 0.25 μg/mL MTX. UL: dead; LL: alive; UR: late apoptosis; 
LR: early apoptosis. 
 
3. Experimental Section 
3.1. Materials  
Syngnathus acus L. was collected from Haikou, Hainan Province (China) in July 2008, and identified 
by one of authors Xiaobo Li. A voucher specimen (SJTU 20080719) was deposited in the School of 
Pharmacy, Shanghai Jiao Tong University. 
DEAE Sepharose Fast Flow and Superdex-75 were obtained from Amersham, USA. RNase A and 
TX0112 Dialysis bags (molecular weight cut-off 14 kDa) were provided by Sangon bioengineering Ltd., 
Inc., China. MTT, Tris, SDS, Hoechst 33342, acrylamide and PI were purchased from Sigma, USA. 
Trysin-EDTA was provided by Biochrom AG, Germany. Coomassie brilliant blue G-250 and bovine 
serum albumin were obtained from Sino-American Biotechnology Co., USA. Molecular weight markers Mar. Drugs 2012, 10 46 
 
 
were obtained from Fermentas, Lithuania. 100 bp DNA marker was provided by MBI, USA. MTX, CTX, 
and 5-Fu were provided by Shanghai Hualian Pharmaceuticals Co., Ltd, China. Universal Genomic 
DNA extraction kit was provided by Takara Bio. Inc., Japan. All other chemicals and reagents used were 
of analytical grade. 
3.2. Cell Lines and Animals  
Four tumor cell lines (A549, CCRF-CEM, LoVo, L1210), and six human non-tumor cell lines (HCF, 
HE-21, HFL-1, HL-7702, PBMC, RPTEC) were provided by Shanghai Institutes for Biological 
Sciences, Chinese Academy of Sciences.  
Male ICR mice (6 weeks old) with an average body mass of 20.0 ± 1.0 g at the time of study initiation, 
provided by Shanghai Laboratory Animal Center of Chinese Academy of Sciences (Certificated No: 
SCXK (Hu) 2007-0018). The animals were housed ten per cage at 22 ± 1 °C and 50 ± 10% relative 
humidity, and subjected to a 12 h light/12 h dark cycle. They were acclimatized for 5 days before use and 
provided food and water ad libitum. The use of animals in this project was approved and in compliance 
with the regulations of the Institutional Animal Care and Use Committee of the School of Pharmacy, 
Shanghai Jiao Tong University, Shanghai, China.  
3.3. Bioassay-Guided Isolation of Antitumor Protein 
All purification steps were carried out at 4 °C. The piece (100 g) of the whole body of S. acus was 
washed with tap water two times and then extracted with 800 mL distilled water for 12 h under 
continuous stirring. After centrifugation (3000 g, 30 min), the supernatant was collected and 
subsequently fractionated by salting out with ammonium sulfate, up to 80% saturation in 30 min. The 
protein precipitate was collected by centrifugation (4800 g, 30 min), dissolved in 30 mL of distilled water 
and dialyzed against 3 L distilled water for 6 h three times to completely remove residual ammonium 
sulfate. The dialyzed solution was freeze-dried to give the crude protein of S. acus (CPAS). 
CPAS was loaded onto a DEAE Sepharose Fast Flow column which was preequilibrated with 20 mM 
Tris-HCl buffer (pH 8.0), and then eluted with increasing concentration of NaCl prepared in 20 mM 
Tris-HCl buffer. The fractions eluted were collected, dialyzed against distilled water and freeze-dried for 
the proliferation inhibition assay. The fraction with the optimal activity was subsequently injected into a 
Superdex-75 column and eluted with 0.2 M NaCl prepared in 20 mM Tris-HCl buffer. Each peak 
fraction was collected, dialyzed against distilled water and freeze-dried for the subsequent proliferation 
inhibition assay. 
Proliferation inhibition in vitro was evaluated by MTT method [20], and expressed as IC50, i.e., the 
sample concentration able to inhibit cell growth by 50% compared with the untreated control. All 
experiments were carried out in triplicate, and data in the form of mean ± SD were presented. 
3.4. Characterization of Antitumor Protein 
3.4.1. Molecular Weight Determination 
The molecular weight of protein was determined by SDS-PAGE and MALDI-TOF-MS. Mar. Drugs 2012, 10 47 
 
 
SDS-PAGE: SDS-PAGE was performed with a mini-gel apparatus (VE-180 vertical electrophoresis 
bath, Tanon, China). The samples were analyzed according to the method in Laemmli [21], using an 
acrylamide concentration of 5% for the stacking gel and 12% for the running gel. Protein bands were 
detected by GIS 2010 Gel Imaging System (Tanon, China) and molecular weight was calculated 
according to the standard curve. 
MALDI-TOF-MS: Protein sample was mixed with matrix solution (sinapinic acid in 50% acetonitrile 
and 0.1% trifluoroacetic acid) and the mixture was spotted on the MALDI target plate. The spectrum 
was acquired in positive ion mode at 20 kV in linear mode on a MALDI-4800-TOF-TOF-MS (ABI Inc.). 
3.4.2. Isoelectric Point Determination 
Isoelectric point of protein sample was determined by immobilized pH gradient (IPG) isoelectric 
focusing-polyacrylamide gel electrophoresis (IEF-PAGE), which was carried out on PROTEAN IEF 
Cell (BIO-RAD) according to the manufacturer’s protocol. The gel was made with ampholine at pH 
range from 4.5 to 9.6 and stained with coomassie brilliant blue R250 [22]. 
3.4.3. Carbohydrate Concentration Assay 
The total neutral sugar content of the purified protein was determined by the modified version of the 
colorimetric phenol-sulfuric acid method using glucose as standard. The absorbance at 490 nm was used 
to determine the amount of carbohydrate in the sample [23]. 
3.4.4. Analysis of Amino Acid Composition 
The composition of amino acids was analyzed by an L-8900 amino acid automatic analyzer (Hitachi, 
Japan). Sample was applied into hydrolysis tube and hydrolyzed with 6 M HCl at 110 °C for 18 h. The 
hydrolysate was dried, dissolved in 0.02 N HCl, and centrifuged at 10,000 rpm for 15 min. The amino 
acid compositions were then obtained by automatic analysis algorithm of the amino acid   
automatic analyzer.  
3.4.5. Analysis of the N-Terminal Amino Acid Sequence  
The purified protein was electroblotted to PVDF membrane after SDS-PAGE. The transferred 
visualized bands in PVDF membrane were cut and applied to a protein sequencer PROCISE 491 
(Applied Biosystems, USA). The amino acid sequence was analyzed by Edman degradation, with 
chemicals and the program supplied by the manufacturer. Homology search of N-terminal sequence was 
performed using BLAST software in NCBI.  
3.5. Antitumor Evaluation 
3.5.1. Evaluation of Antitumor Activity in Vivo 
Solid tumors: ICR mice were inoculated hypodermically on the left flank with 1 × 10
7 cells of S180. 
Samples and CTX (positive control) were administered intraperitioneally (i.p.) once a day for 7 days 
starting from 24 h after tumor implantation, and mean tumor weight (MTW) of each group was Mar. Drugs 2012, 10 48 
 
 
examined on 11th day. Antitumor activity was evaluated in terms of the percentage of reduced tumor 
weight (growth inhibition %) over the control group. Growth inhibition (%) = (1 − MTW of treated 
group/MTW of control group) × 100 [24].  
Ascitic tumors: ICR mice were inoculated (i.p.) with 1 × 10
6 cells of H22 and randomly divided  
into 5 groups of mice. Samples, NS and 5-Fu were administered (i.p.) once a day for 7 days starting from 
24 h after tumor implantation. The mean survival time (MST) of each group was examined on the 9th 
day. Antitumor activity was evaluated in terms of life prolongation rate calculated by the following: life 
prolongation rate (%) = (MST of treated group/MST of control group − 1) × 100 [24]. 
3.5.2. Induction of Apoptosis in Tumor Cells 
3.5.2.1. Cell Cycle Analysis 
A549 cells were seeded at 1 × 10
6/mL in six-well plates and treated with sample. After incubation for 
24 h, the cells were collected and washed with PBS for three times and then were resuspended in  
5 μg/mL PI (1 mL) containing 100 U/mL RNase A. The DNAs of cells were stained by PI for 30 min, 
while the RNAs were removed by digestion with RNase A at 4 °C for 30 min. The DNA contents of the cells 
were determined at an excitation wavelength of 488 nm by FACScan (BD Biosciences, CA, USA). 
3.5.2.2. Comet Assay 
A549 cells were seeded at 5 × 10
6/mL in six-well plates and incubated for 24 h. After treated with 
sample for 24 h, the cells were collected and total genomic DNA was extracted according to the protocol 
described in Universal Genomic DNA extraction kit (Takara, Japan). The DNA samples were resolved 
on 1.0% agarose gel, electrophoresis, stained with 0.5 μg/mL of ethidium bromide and photographed by 
GIS 2010 Gel Imaging System (Tanon, China). 
3.5.2.3. Cell Morphological Assessment 
A549 cells were seeded at 1 × 10
5/mL in 24-well plates and treated with different concentration 
samples (40, 200 and 1000 μg/mL, respectively) for 24 h. After the treatment, all floating and attached 
cells were harvested with 0.02% (w/v) EDTA and 0.25% (w/v) trypsase, fixed with 4% (w/v) 
paraformaldehyde for 20 min and permeabilized by 0.2% Triton X-100 for 10 min. When washed with 
PBS buffer, cells were stained by fluorochrome dye Hoechst 33342 for 15 min in dark and observed 
under an inverted fluorescence microscope (Olympus IX51, Tokyo, Japan) with a peak excitation 
wavelength of 340 nm. 
3.5.3. Cooperativity with Chemotherapeutics 
The inhibitions of only chemotherapeutics and combination of chemotherapeutics and protein sample 
(0.20 mg/mL) were determined by MTT, respectively. SI was calculated by the following formula:  
SI = Ic+p/(Ic + Ip − Ic × Ip), Ic and Ip mean inhition of chemotherapeutics and protien, Ic+p means inhibition 
of combination of chemotherapeutics and protein [25]. To further confirm the synergic action between 
chemotherapeutics and protein, their induction apoptosis on Lovo cells was further evaluate by flow 
cytometer with Annexin V-PI double staining. Mar. Drugs 2012, 10 49 
 
 
3.6. Statistical Analysis 
The results were expressed as mean ± SD. Differences between groups were evaluated by one-way 
analysis of variance (ANOVA) followed by Dunnett’s test with the aid of SPSS 16.0 software package 
[26]. Statistical significance is expressed as * p <0.05, ** p < 0.01. 
4. Conclusions 
A novel protein Syngnathusin was successfully purified from Syngnathus acus by bioactive guideline 
isolation. It showed strong and selective antitumor activities in vivo and in vitro. In addition, it could 
combine the antitumor activities with MTX. Syngnathusin is a promising protein for the development of 
a new antitumor agent. 
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